Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about UCB
11/14 UCB : New study data shows prior osteoporotic fractures put women at increased r..
11/10 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
11/06 UCB : Dermira and UCB Agree to End Collaboration Agreement for CIMZIA …
10/20 UCB FIRST NINE MONTHS INTERIM REPORT :  Strong 9 …
10/20 UCB : By the time you finish reading this headline another person …
10/17UCB SA : quaterly earnings release
10/17 UCB : Transparency notification The Capital Group Companies
10/13 UCB : Transparency notification The Capital Group Companies
09/15 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
09/14 UCB : New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of..
09/11 UCB : EVENITYTM (romosozumab) ARCH Study Results Published in the New England &h..
09/08 UCB : highlights latest EVENITY™ (romosozumab) research at the American So..
08/28 UCB : S.A. - Transparency notification Wellington
08/23 UCB : Transparency notification Wellington
08/03 UCB : S.A. - Transparency notification The Capital Group Companies
More most relevant news
All news about UCB
11/14 UCB : New study data shows prior osteoporotic fractures put women at increased r..
11/10 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
11/06 UCB : Dermira and UCB Agree to End Collaboration Agreement for CIMZIA …
10/20 UCB FIRST NINE MONTHS INTERIM REPORT :  Strong 9 …
10/20 UCB : By the time you finish reading this headline another person …
10/17UCB SA : quaterly earnings release
10/17 UCB : Transparency notification The Capital Group Companies
10/13 UCB : Transparency notification The Capital Group Companies
09/21 UCB : Studies from UCB S.A. Reveal New Findings on Extracellular Space (Quantita..
09/15 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
More news
Sector news : Pharmaceuticals - NEC
12:17aDJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/16 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/06 Dermira to returns rights to psoriasis candidate Cimzia back to UCB; shares d..
07/31 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
07/17 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
Financials (€)
Sales 2017 4 350 M
EBIT 2017 990 M
Net income 2017 629 M
Debt 2017 611 M
Yield 2017 1,97%
P/E ratio 2017 17,46
P/E ratio 2018 15,28
EV / Sales 2017 2,89x
EV / Sales 2018 2,66x
Capitalization 11 945 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 65,8 €
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB0.82%14 080
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550